Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibrin sealant patch - Takeda

Drug Profile

Fibrin sealant patch - Takeda

Alternative Names: Absorbable fibrin sealant patch; Fibrin-sealant; Medicated sponge - Nycomed; TachoComb; TachoSil

Latest Information Update: 14 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer Takeda Pharmaceuticals International GmbH
  • Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Fibrinogen replacements; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 08 May 2019 Takeda enters into agreement with Ethicon to sell Fibrin sealant patch (TachoSil®) for haemostasis in surgery
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top